Stem Cell Therapy for Multiple Sclerosis - A Pipeline Analysis report

Stem Cell Therapy for Multiple Sclerosis - A Pipeline Analysis report

This pipeline analysis report offers detailed insights into the clinical trials landscape of the stem cell therapy for multiple sclerosis including molecules at different development stages. Moreover, the report also offers information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administration.

Key questions answered in the report include

  • What are the stem cell molecules in the various development stages for multiple sclerosis?
  • What are the companies that are currently involved in the development of stem cell therapy molecules for multiple sclerosis?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?
  • Detailed profiling of each active molecule.


  • Executive summary
  • Scope of the report
  • Research methodology
  • Stem cell therapy for multiple sclerosis: An insight
    • Introduction
  • Major regulatory authorities
    • US
      • Table Drug approval process by US FDA
    • Europe
    • Japan
    • Australia
    • China
  • Pipeline landscape
    • Table Pipeline landscape
  • Comparative analysis
    • Table Pipeline molecules in different developmental stages 2017
    • Mid-stage molecules (Phase I/II), 2017
      • Table Overview: Human umbilical cord mesenchymal stem cells
      • Table Clinical trials description of Huma umbilical cord mesenchymal stem cells
    • Early-stage molecule (Phase I), 2017
      • Table Overview: Autologous adipose-derived mesenchymal cells
      • Table Clinical trials description of Autologous adipose-derived mesenchymal cells
      • Table Overview: PDA-001
      • Table Clinical trials description of PDA-001
    • Pre-clinical and discovery stage molecules, 2017
      • Table Overview: MultiStem
      • Table Overview: MSC-NTF
      • Table Overview: AST-OPC1
      • Table Overview: NSI-777
      • Table Overview: ALLOCETRA
      • Table Overview: NeurArrest
      • Table Overview: Adult stem cell therapy
    • Inactive (status unknown and terminated) molecules, 2017
      • Table Overview: Umbilical cord-derived mesenchymal stem cells
      • Table Clinical trials description of Umbilical cord-derived mesenchymal stem cells
      • Table Overview: Autologous bone marrow-derived mononuclear stem cells
      • Table Clinical trials description of Autologous bone marrow-derived mononuclear stem cells
  • Indication analysis
    • Table Pipeline molecules as per types of multiple sclerosis
  • Therapeutic assessment by RoA
    • Table Assessment by RoA
  • Key companies
    • Active companies: Category and parameters
      • Table Active companies: Category and parameters 2017
      • Table Segmentation of companies 2017
      • Table Overview: American CryoStem 2017
      • Table Overview: Asterias Biotherapeutics 2017
      • Table Overview: Athersys 2017
      • Table Overview: Brainstorm Cell Therapeutics 2017
      • Table Overview: Celgene Cellular Therapeutics 2017
      • Table Overview: Cell Cure Neurosciences 2017
      • Table Overview: DaVinci Biosciences 2017
      • Table Overview: Enlivex Therapeutics 2017
      • Table Overview: Neuralstem 2017
      • Table Overview: Translational Biosciences 2017
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook